JP2021517588A5 - - Google Patents
Info
- Publication number
- JP2021517588A5 JP2021517588A5 JP2020571917A JP2020571917A JP2021517588A5 JP 2021517588 A5 JP2021517588 A5 JP 2021517588A5 JP 2020571917 A JP2020571917 A JP 2020571917A JP 2020571917 A JP2020571917 A JP 2020571917A JP 2021517588 A5 JP2021517588 A5 JP 2021517588A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- pharmaceutical composition
- cxcr4
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024067425A JP2024105305A (ja) | 2018-03-13 | 2024-04-18 | 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862642313P | 2018-03-13 | 2018-03-13 | |
| US62/642,313 | 2018-03-13 | ||
| PCT/IB2019/052042 WO2019175802A1 (en) | 2018-03-13 | 2019-03-13 | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024067425A Division JP2024105305A (ja) | 2018-03-13 | 2024-04-18 | 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517588A JP2021517588A (ja) | 2021-07-26 |
| JP2021517588A5 true JP2021517588A5 (enExample) | 2022-06-06 |
| JP7561631B2 JP7561631B2 (ja) | 2024-10-04 |
Family
ID=66286540
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571917A Active JP7561631B2 (ja) | 2018-03-13 | 2019-03-13 | 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 |
| JP2024067425A Withdrawn JP2024105305A (ja) | 2018-03-13 | 2024-04-18 | 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024067425A Withdrawn JP2024105305A (ja) | 2018-03-13 | 2024-04-18 | 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230181635A1 (enExample) |
| EP (1) | EP3765519B1 (enExample) |
| JP (2) | JP7561631B2 (enExample) |
| KR (1) | KR102693317B1 (enExample) |
| CN (1) | CN112513079A (enExample) |
| ES (1) | ES2973728T3 (enExample) |
| WO (1) | WO2019175802A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL276365B2 (en) | 2018-02-01 | 2023-10-01 | Nkmax Co Ltd | A method for the production of natural killer cells and a preparation for cancer treatment |
| CN117715647A (zh) * | 2021-04-08 | 2024-03-15 | 埃迪瓦生物治疗公司 | 用nk细胞和cd38靶向抗体治疗癌症 |
| CN115836666B (zh) * | 2021-09-20 | 2024-11-01 | 上海中医药大学附属龙华医院 | 原位骨肉瘤和肺转移瘤小鼠模型及其制法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| MX2009003306A (es) * | 2006-10-02 | 2009-04-23 | Medarex Inc | Anticuerpos humanos que se unen a cxcr4 y sus usos. |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| CN102027015A (zh) | 2008-05-14 | 2011-04-20 | 伊莱利利公司 | 抗cxcr4抗体 |
| US7892546B2 (en) | 2008-05-14 | 2011-02-22 | Eli Lilly And Company | Anti-CXCR4 antibodies |
| EP2172485A1 (en) | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
| CN102428173B (zh) * | 2009-03-26 | 2014-07-30 | 细胞维护北欧制药公司 | Nk细胞的扩增 |
| US20140120555A1 (en) | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
| EP2734234A4 (en) | 2011-07-20 | 2015-01-28 | Medimmune Ltd | ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF |
| CN104039320B (zh) | 2011-11-09 | 2019-10-15 | 百时美施贵宝公司 | 血液恶性肿瘤用抗-cxcr4抗体的治疗 |
| CA2919790C (en) | 2013-08-02 | 2018-06-19 | Pfizer Inc. | Anti-cxcr4 antibodies and antibody-drug conjugates |
| CN105899536A (zh) | 2013-11-06 | 2016-08-24 | 百时美施贵宝公司 | 用抗cxcr4抗体治疗c1013g/cxcr4相关的华氏巨球蛋白血症 |
| US11639384B2 (en) * | 2014-10-28 | 2023-05-02 | University Children's Hospital Tübingen | Treatment of pediatric BCP-ALL patients with an anti-KIR antibody |
| US10813952B2 (en) * | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| JP2018516969A (ja) * | 2015-06-12 | 2018-06-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 |
| TW201718851A (zh) * | 2015-09-18 | 2017-06-01 | 通用醫院公司 | 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途 |
-
2019
- 2019-03-13 ES ES19719623T patent/ES2973728T3/es active Active
- 2019-03-13 EP EP19719623.1A patent/EP3765519B1/en active Active
- 2019-03-13 KR KR1020207029169A patent/KR102693317B1/ko active Active
- 2019-03-13 CN CN201980018712.7A patent/CN112513079A/zh active Pending
- 2019-03-13 WO PCT/IB2019/052042 patent/WO2019175802A1/en not_active Ceased
- 2019-03-13 JP JP2020571917A patent/JP7561631B2/ja active Active
- 2019-03-13 US US16/979,968 patent/US20230181635A1/en active Pending
-
2024
- 2024-04-18 JP JP2024067425A patent/JP2024105305A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516045A5 (enExample) | ||
| CN102264385B (zh) | 含特异性识别cd38的抗体和苯丙氨酸氮芥的抗肿瘤组合 | |
| JP2018516969A5 (enExample) | ||
| JP6215429B2 (ja) | Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ | |
| JP6130871B2 (ja) | Ｃｄ３８を特異的に認識する抗体とビンクリスチンとを含有する抗腫瘍組合せ | |
| JP2019533981A5 (enExample) | ||
| CN102264386A (zh) | 含特异性识别cd38的抗体和阿糖胞苷的抗肿瘤组合 | |
| CN107148285A (zh) | 吡咯并苯并二氮杂*‑抗体缀合物 | |
| CN103282050A (zh) | 包含特异性识别cd38的抗体和硼替佐米的抗肿瘤组合 | |
| WO2016204193A1 (ja) | 抗がん剤 | |
| CN106659772A (zh) | 在疾病和紊乱的治疗中调节肾酶的组合物和方法 | |
| CN112292128A (zh) | Ep4抑制剂和其用途 | |
| US20220411512A1 (en) | Combination treatment for cancer | |
| JP2021517588A5 (enExample) | ||
| JP2022526841A5 (enExample) | ||
| JP2024105305A (ja) | 癌免疫療法のための活性化および拡張ナチュラルキラー細胞と組み合わせた抗ｃｘｃｒ４抗体 | |
| TW202102216A (zh) | 抗腫瘤組合物 | |
| CN114867493B (zh) | Kir3dl3是免疫系统的抑制性受体及其用途 | |
| TW202541808A (zh) | 抗癌組合治療 | |
| JP2012025694A (ja) | 癌治療剤 | |
| EP2968539A1 (en) | Combination/adjuvant therapy for wt-1-positive disease | |
| WO2019149219A1 (zh) | 抗-cd3免疫毒素联合抗-pd-l1单域抗体治疗癌症的应用 | |
| RU2827900C1 (ru) | Kir3dl3 - ингибирующий рецептор иммунной системы и его применение | |
| HK40120537A (zh) | 抗肿瘤组合物 | |
| CN116194142A (zh) | 通过施用pd-1抑制剂治疗癌症疼痛的方法 |